Background: Despite recent progress in diagnostic and oncology therapy, lung cancer constitutes the leading cause of cancer-associated mortality worldwide, with approximately 85% of lung cancer cases being nonesmall cell lung cancer (NSCLC) histological type. The study of epidermal growth factor receptor (EGFR) gene mutational profile in nonesmall cell lung cancer patients has a special clinical significance in the selection of patients for tyrosine-kinase inhibitor therapy. The aim of this study was to identify the frequency and spectrum of EGFR mutations in a cohort of Moroccan patients with lung cancer using the ADx-ARMS technology. Method: We performed a retrospective study by processing 164 cases of NSCLC patients recruited between March 2015 and March 2018. Using the DNA extracted from the formalin-fixed paraffin-embedded FFPE tissue, we attempted to identify somatic mutations in exons 18 to 21 of the tyrosine-kinase "TK" domain of EGFR gene. We evaluated EGFR mutations using High Resolution Melt (HRM) polymerase chain reaction (PCR) and real time PCR "ADx-ARMS technology" for results confirmation. Results: Among the positive mutant cases, the resulting mutations were as follows: 70% of patients have a deletion in exon 19, 10% in exon 21(L858R), 10% in exon 20 (6.7% T790M and 3.3% S768L) and 10% in exon 18 (G719A/C). The EGFR mutations were more frequent among males compared to females (51,7% and 48,3% respectively), all of the positive patients with EGFR mutations were adenocarcinoma (ADK) and 37,9%% of them were smokers. Conclusion: The presented method can be implemented at the laboratories to identify the most frequent EGFR mutations that are important for targeted therapy of advanced lung cancer patients.
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The Background: Small cell lung cancer (SCLC) accounts for about 10%-15% of the total number of lung cancer and with a poor outcome. Especially in extensive-stage (ED) small cell Lung Cancer, the 5-year survival rate is less than 5%. To improve the survival outcome, a number of therapeutic approaches have been tried, such as dose dense chemotherapy, high-dose chemotherapy, maintenance therapy and consolidation chemotherapy. However, the result was of no proven benefit. Patients with a lower pretreatment circulating VEGF levels were more likely to respond to chemotherapy compared to those with higher levels of VEGF. The results from these studies suggest that VEGF may be linked to overall poor outcome in SCLC. Therefore, inhibition of VEGF represents a rational therapeutic strategy for evaluation in SCLC. Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). Although there have been few studies of small cell Lung Cancer treated with apatinib so far, a retrospective study showed that apatinib exhibits modest activity and acceptable toxicity for the heavily pretreated patients with extensive-stage SCLC. The disease control rate was 81.8%. However, is there a benefit in survival of apatinib as maintenance therapy in extensive-stage SCLC is unclear. Therefore, the aim of this study was to analyze the efficacy and safety of apatinib as maintenance therapy in extensive-stage SCLC. Method: Retrospective analysis of 23 cases extensive-stage SCLC that admitted to The Affiliated Cancer Hospital of Zhengzhou University from January 2015 to December 2017. The patients without progression after induction chemotherapy, received apatinib 250mg per day until disease progression or unacceptable toxicity occurs. We analyzed the median progression-free survival (PFS), median Overall survival (OS) and safety. Results: Of 23 enrolled patients,1 was lost to follow-up. The median PFS from the time of maintenance therapy was 4.1 months (95%CI,3.63 to 4.57 months). The median PFS from the time of induction chemotherapy was 8.3 months (95%CI,7.20 to 9.40 months). The median OS from the time of maintenance therapy was 12.5 months (95%CI,5.51 to 19.49 months). The median OS from the time of induction chemotherapy was 17.0 months (95%CI,9.86 to 24.14 months). The most frequent treatmentrelated adverse events were hand-foot syndrome (43.5%, 10/23), secondary hypertension (30.4%, 7/23). Fatigue, proteinuria, nausea, oral mucositis were 17.4%, 13.0%, 13.0%, 8.7%, respectively. Hematologic toxicity includes thrombocytopenia (30.4%), leucopenia (26.1%), and anemia (17.4%). Main grade 3 or 4 toxicities were hand-foot syndrome (8.7%, 2/23), and hypertension (4.3%, 1/23 Background: Lung cancer is the most common cause of death from cancer worldwide, estimated to be responsible 1.59 million deaths, representing 19.4% of all cancer types. Representing 80e85% of all cases nonesmall cell lung cancer (NSCLC) is the most predominant type of lung cancer. Lung cancer has been recognized as a complex multifactorial disease resulting from the interactions between various genetic and environmental factors. Identification of genes involved in the occurrence and development of lung cancer could contribute to further understanding of the underlying mechanisms, and even a very important additional appropriate prevention strategies and targeted treatments for reducing lung cancer burden. Many studies have suggested that key cytokines in inflammation pathways may exert important roles in the etiology of lung cancer. The aim of this study was to investigate whether common variants in inflammatory and immune response genes influence lung cancer risk in Moroccan patients. Method: Using a candidate gene approach, 6 single nucleotide polymorphisms (SNPs) in 4 genes were assessed in 117controls and 117 lung cancer patients. Genotyping was performed with the TaqMan® allelic discrimination technology. The results were analysed using SPSS 24.0 software. Results: Among the 5 studied genes, we found a significant association for the MIF (rs755622) (OR¼1.63; 95% confidence interval 1.04-2.56; p ¼0.03), IL-6 (rs2069840) (OR¼1.63; 95% confidence interval 1.08-2.47; p ¼0.01) and STAT3. No significant association was observed for the remaining SNPs in the following genes: IL17A rs7747909, IL-6R_rs2228145, IL6ST_rs2228044. Conclusion: The results founded suggest the important role of genetically determined high inflammatory response in the pathogenesis of lung cancer in the Moroccan population. Keywords: Lung cancer, Inflammatory system, Cytokines, polymorphisms
